Holen Sie sich die Stockscreener-App
3.42
2.01%
-0.07
Handel nachbörslich:
3.43
0.01
+0.29%
Briacell Therapeutics Corp Aktie (BCTX) Neueste Nachrichten
BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board - GuruFocus
BriaCell (BCTX) Receives Positive Update from Data Safety Monito - GuruFocus
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer - Investing News Network
BriaCell Therapeutics Corp. (BCTX) Stock Price, News, Quote & History - Yahoo Finance
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - lincolnjournal.com
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT at ASCO 2026 - Investing News Network
Breast cancer vaccine Bria-IMT shows 16.6-month survival, home-use potential - Stock Titan
BCTXL Price Today: BriaCell Therapeutics Corp. Warrant expiring 2031 Stock Price, Quote & Chart | MEXC - MEXC
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 - Investing News Network
BriaCell develops ovarian cancer immunotherapy candidate - Investing.com India
Interfor Corporation - Baystreet.ca
BriaCell Therapeutics Developing Ovarian Cancer Immunotherapy Candidate - Moomoo
BriaCell develops ovarian cancer immunotherapy candidate By Investing.com - Investing.com Canada
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+ - Investing News Network
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™ - The Manila Times
Briacell expands pipeline to include an ovarian cancer immunotherapy candidate, Bria-Ova+(TM) - marketscreener.com
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer - Sahm
TradingKey - TradingKey
BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment - GuruFocus
BriaCell completes manufacturing of prostate cancer therapy - Investing.com
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+ for Prostate Cancer - Investing News Network
BriaCell completes manufacturing of prostate cancer therapy By Investing.com - Investing.com South Africa
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - Sahm
BriaCell Therapeutics Corp. Revenue Breakdown – NASDAQ:BCTXZ - TradingView
BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - Investing News Network
BriaCell (BCTX) Expands Clinical Trial Network for Advanced Brea - GuruFocus
Penn Medicine joins BriaCell phase 3 breast cancer trial By Investing.com - Investing.com Nigeria
Penn Medicine joins BriaCell phase 3 breast cancer trial - Investing.com
BriaCell enrolls 230+ patients in Phase 3 breast cancer trial, interim data expected in 2026 - Pluang
BriaCell enrolls over 230 patients in phase 3 breast cancer trial - Investing.com UK
BriaCell enrolls over 230 patients in phase 3 breast cancer trial By Investing.com - Investing.com South Africa
BriaCell Phase 3 Bria-IMT Study Enrollment Surpasses 230 Patients - Investing News Network
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients - The Manila Times
MSN Money - MSN
BriaCell Therapeutics: Redefining Oncology with Personalized Cancer Immunotherapy - Investing News Network
Free float of BriaCell Therapeutics Corp. – NASDAQ:BCTXZ - TradingView
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):